News

A look at the questions you should be asking during the decision-making process of picking a telehealth vendor.

Neurology News Network for the week ending July 4, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 3, 2020.

An NIH-funded study provided supporting evidence of an association between high levels of gram-negative bacteria and a stroke-, seizure-, and headache-inducing vascular abnormality.

In the wake of the COVID-19 pandemic, health care providers and patients have had to quickly adapt to new formats of care models to promote safety while retaining care standards.

Fred Cohen, MD, offers insight on his study exploring the utility of combined Botox with anti-CGRP preventives for patients with chronic migraine.

Andrew Russman, DO, guest editor for NeurologyLive, provides insight on how stroke care has changed during the COVID-19 pandemic.

During DBS stimulation “on” periods, all patients experienced varying degrees of dysphagia, with significant improvements when stimulation was “off.”

Biohaven’s verdiperstat has entered a phase 3 trial for the treatment of multiple system atrophy, with a new drug application submission on the agenda for late 2021.

Kottil Rammohan, MD, director of the MS Division and Multiple Sclerosis Center of Excellence at the University of Miami, discussed the EMD Serono agent’s history and advantages for the patient community.

Notably, the cohort assessment did not identify a link between exposure to disease-modifying therapies and COVID-19 severity.

No differences were observed between the insulin and placebo groups on several clinical outcome measures as well as biomarker evaluations.

An in-depth look into the expanding landscape of multiple sclerosis treatments that target bruton tyrosine kinase.

People with Down syndrome may be a suitable population for clinical trials for Alzheimer disease as prevalence ranges from 90% to 100% by the seventh decade of life.

In this Peer Exchange, sleep experts provide insight into the latest narcolepsy treatments and areas that require further research.

The sBLA for onabotulinumtoxinA is supported by the findings from a randomized, double-blind phase 3 study evaluating the safety and efficacy of onabotulinumtoxinA in more than 100 pediatric patients.

Cancer centers providing care for adolescent and young adult cancer survivors may consider committing resources to routinely screen for sleep disorders and to support patient access to evidence-based insomnia treatment.

In part 2 of this interview, the associate director of the Center for the Aging Brain at Montefiore Medical Center anticipates life with telemedicine after the pandemic and describes the at-home advantage it gives clinicians.

The neurologist at Mayo Clinic in Phoenix, Arizona, discussed the growing variety of treatment options and the progress the migraine community has made on the management of this disease.

Neurology News Network for the week ending June 27, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 26, 2020.